ArticleGastrointestinal cancer research : GCR2008
Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.World journal of gastroenterology · 2015Guideline
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.Cancer chemotherapy and pharmacology · 2013Trial
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Trial
- Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.Current oncology (Toronto, Ont.) · 2022Article
- Article
- Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy.Seminars in interventional radiology · 2020Review
- Synchronous NET and colorectal cancer development: a case report.Surgical case reports · 2020Article
- Article
- Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary.Pancreas · 2019Review
- Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.Journal of gastrointestinal oncology · 2019Article
- Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.Medical oncology (Northwood, London, England) · 2017Article
- Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?Journal of gastrointestinal oncology · 2016Review
- The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.Cancer medicine · 2016Review
- Duodenal neuroendocrine tumor and the onset of severe diabetes mellitus in a US veteran.SAGE open medical case reports · 2016Article
- Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor.Case reports in endocrinology · 2015Article
- Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.BMC endocrine disorders · 2014Article
- Hepatic arterial embolization in patients with neuroendocrine tumors.Journal of experimental & clinical cancer research : CR · 2014Review
- Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.World journal of gastroenterology · 2014Review
- Lin28B is a novel prognostic marker in gastric adenocarcinoma.International journal of clinical and experimental pathology · 2014Article
- Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine malignancies of the gastroenteropancreatic axis include carcinoid and pancreatic endocrine tumors. These heterogeneous neoplasms arise from the enterochromaffin cells of the gastrointestinal tract and the islet cells of the pancreas. Histologically, most well-differentiated endocrine tumors consist of small, round, monomorphic cells, arranged in islands or trabeculae, with a distinct "salt-and-pepper" pattern of nuclear chromatin. Chromogranin and synaptophysin are useful as immunohistochemical markers of neuroendocrine differentiation. Other common features include the capacity to secrete peptide hormones and biogenic amines. A relatively indolent growth rate is characteristic of most gastrointestinal neuroendocrine tumors, with the exception of poorly differentiated tumors which are usually aggressive. Treatment strategies are designed to limit tumor progression and palliate hormonal syndromes. This article reviews the diverse biologic characteristics of gastrointestinal neuroendocrine tumors and current treatment options for metastatic disease.
Identifiers
19259290PMC2633071W2401079267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.